Key facts
- Notable investors include Arben Ventures, Magnify, UCLA Anderson School of Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Diatom Biolab
- ·The full record, as it builds
Funding rounds
No funding rounds for Diatom Biolab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diatom Biolab
Developer of a bio-server designed to advance wet lab research by making biological discovery as accessible as coding. The company's product automates experiments using programmable droplet manipulation on semiconductor chips, tapping into semiconductor infrastructure for unmatched scalability and cost-efficiency, enabling clients to reduce research costs and increase throughput through extreme miniaturization and massive parallelization.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2024
- Employees
- 3
- Website
- diatombiolab.com/
- Ownership
- Privately Held (backing)
Diatom Biolab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diatom Biolab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diatom Biolab in its N-PORT filings yet. We sweep new filings monthly.